COVID Vaccines: Company Announcements on Development/Regulatory Actions/Procurement/Deployment

Milestones :: Perspectives :: Research


COVID Vaccines: Company Announcements on Development/Regulatory Actions/Procurement/Deployment

Dr. Reddy’s Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India
January 15, 2021
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India. The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India//.

Bharat Biotech Signs Agreement with Precisa Medicamentos For Supply of ‘COVAXINTM’ to Brazil
Hyderabad, January 12, 2020:Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil…
In principle, it is understood between both parties that supplies of COVAXIN™ to be prioritized for the public market, through a direct procurement by the Govt. of Brazil. Supplies to the private market would be based upon receipt of market authorization from ANVISA, the Brazilian regulatory authority…

Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland
Swiss Federal Government has secured 7.5 million doses and first deliveries expected to begin in January
January 12, 2021
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the COVID-19 Moderna Vaccine in Switzerland…

Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India
Dr. Reddy’s submitted the phase 2 safety data for DCGI’s approval to continue phase 3 clinical trials
January 11, 2021

Baxter Biopharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine
:: Agreement will help increase commercial production and promote access in United Kingdom and European markets
:: Manufacturing to take place at Baxter’s state-of-the-art Halle/Westfalen, Germany facility
January 11, 2021